Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

V, a member of K-pop sensation BTS, has revealed that he has been dealing with hearing loss in one ear for about two and a half years.

V, whose real name is Kim Tae-hyung, opened up about the condition for the first time during a livestream amid the band's highly anticipated world tour.

"If the hearing in my left ear is at 100, it's only about 30 in my right," V said.

The 30-year-old singer said his hearing became worse while he was serving in the military. However, he initially ignored the problem, believing it was "a matter of mental strength," BBC reported.

He said he is now taking medication and visiting the hospital regularly.

V Reveals Risk Of Stress Fracture

V also admitted to pushing through pain during BTS' current tour, revealing that he is dangerously close to developing a stress fracture in his leg.

“My shin is right at the point just before a stress fracture. Even today on stage, my heart was set on running around, but it hurt too much at points and I couldn’t," he was quoted as saying by Channel News Asia.

Doctors have warned him about inflammation and early bone damage.

“It hasn’t reached a stress fracture yet, but there’s a lot of inflammation in my shin, and I think there’s some microdamage to the bone. I’ll be careful with myself so I can finish this tour properly,” he added.

BTS is currently halfway through its massive Arirang world tour, which will stop in Singapore in December and conclude in the Philippines in March 2027.

What Is Hearing Loss?

Hearing loss can happen when any part of the ear is not working in the usual way. This includes:

• The outer ear
• The middle ear
• The inner ear
• The hearing or acoustic nerve
• The auditory system in the brain

Hearing loss is a growing health concern worldwide. According to the WHO, more than 1.5 billion people—nearly 20% of the world's population—live with some degree of hearing loss. Of these, approximately 430 million people have disabling hearing loss requiring rehabilitation.

Hearing loss can have a significant impact on a person's life, affecting education and job prospects.

What Causes Hearing Loss?

Hearing loss can occur at any time during life. Causes can range from genetic factors to conditions such as Down syndrome or Usher syndrome.

Other factors include:

• Maternal infections during pregnancy
• Complications after birth
• Spending five days or more in a neonatal intensive care unit (NICU)
• Severe jaundice requiring a blood transfusion

How To Prevent Hearing Loss

To help prevent hearing loss in adults:

• Limit exposure to loud noises above 85 decibels.
• Wear ear protection, such as foam plugs or earmuffs, around heavy machinery or at concerts.
• Keep personal headphone use at safe volumes.
• Manage chronic health conditions such as high blood pressure.
• Avoid putting objects such as cotton swabs inside the ears.

Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.

JP Nadda Under Observation

The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.

“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.

Is Uneasiness A Sign Of Heart Problems?

Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.

Possible warning signs include:

• Unusual fatigue
• Shortness of breath
• Jaw pain
• Irregular heartbeat
• Swollen feet and ankles
• Dizziness
• Cough
• Leg pain or cramps
• Poor sleep

What Is Coronary Angiography?

Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.

A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.

Why Is It Done?

Doctors may recommend coronary angiography for:

• Unexplained chest pain
• Abnormal results from tests such as an ECG, stress test or echocardiogram
• A heart attack, to locate a blocked artery
• Unexplained heart failure or cardiac arrest
• Certain congenital heart conditions

Why Are Heart Checkups Important?

Regular checkups can help detect heart disease early and monitor risk factors such as:

• Blood pressure
• Cholesterol
• Blood sugar

Who Should Consider Regular Heart Checkups?

Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.

Regular heart checkups are particularly important for people who:

• Are above 30
• Have a family history of heart disease
• Have high blood pressure, diabetes or high cholesterol
• Smoke or frequently consume alcohol
• Lead a sedentary lifestyle
• Are overweight or obese
• Experience ongoing stress

Common Tests Included In A Heart Checkup

Depending on individual risk factors, a heart checkup may include:

• Blood pressure measurement
• Blood tests for cholesterol, triglycerides and blood sugar
• ECG to assess heart rhythm
• Echocardiography to assess heart structure and function
• TMT or stress test to assess the heart during exertion

Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.

Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.

The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.

Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.

62 Death Reports Involving GLP-1 Medicines

Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.

Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.

The reported deaths included:

• Semaglutide — 37 reports
• Tirzepatide — 9 reports
• Liraglutide — 11 reports
• Dulaglutide — 5 reports

The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.

GLP-1 Drugs Carry New Warning For Rare Eye Condition

The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.

Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.

NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.

GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.

“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.

Death Reports From Other Countries

The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.

Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.

In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.

However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.